Canada markets open in 1 hour 4 minutes

Khiron Life Sciences Corp. (KHRNF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.2260+0.0060 (+2.73%)
At close: 3:59PM EDT
Sign in to post a message.
  • k
    kalle
    Bought more ,excellent price, like a company that buys back some of its own shares shows confidence in their own product.
  • J
    Jonn
    How's that buy back going? Someone please explain to me why a company would announce a buy back TWICE and then not really BUY BACK their shares.
  • E
    Ernest
    Khiron investor relations is relatively forthcoming with information (they don't like talking about things too specifically as they don't want to tip their hand). Below is a question posed to IR but another investor.

    Hello Paola!

    I hope all is well. Just wanted to touch base about the Brazilian expansion, as Mexico seems to be problematic at the moment.

    Will this expansion take the form of Peru, where Khiron had a partnership clinic to expand the Zerenia brand? How is that partnership going anyways, with less control? Can we expect insurance coverage in Peru or Brazil in the near term?

    RESPONSE:

    Thanks for reaching out. First of all, we would say that Mexico is not problematic at the moment. We are working on several initiatives there and we are not losing time. As Alvaro mentioned in the conference, we are not planning to announce deals until we are on verge of execution and are sure that these announcements will not derail our execution. We ask you to be patient, but the reality is that Khiron is going to Mexico, that the team is committed to finding the most efficient and compliant way to getting there. Breaking ground is not easy, but we welcome it and we will be very successful in Mexico. Secondly, in Peru, we launched the commercial operations of the clinic in September, after doing a soft opening and now we are working on the codification of our newly approved branded product Alixen. Our partner is committed to the capital investments needed for growth and to attract demand and we will see that uptick in prescriptions soon. As for Brazil, as Alvaro mentioned we are looking to open a Zerenia in Rio soon.
  • D
    Dan
    @jonn I don’t think you understand how a buyback works. The buyback grants them the right to purchase shares, it is not a commitment. There is no point in purchasing shares if they will just go back down the next day. There is not enough volume for a buyback to make sense right now.
  • D
    DFV_Fan
    Alvaro just bought 50,000 shares! $14,900 well spent.
  • M
    Michael
    Check my post from months 3 months ago, I said this is going to the twentys..
  • E
    Ernest
    For those of you looking for reasons to buy and average down?think about it?85%+ margin?crazy growth in Germany?new Director in Brazil who just happens to be the doctor with the most #$%$ prescriptions in the country for sure clinic in place by 12/31?partnerships in Mexico already announced?Mexican Congress going back into session now?new clinic in Peru?2 large Colombian insurance companies on board?Kicksss lady in charge in Europe?$29M cash on hand
  • T
    Thomi
    In Sept 2020 I had the great pleasure and opportunity to meet Khirons Chairman Chris Naprawa in Zurich/Switzerland.We had a great discussion about Khiron, it’s business model and way forward.On Aug 26 2021 I traveled to Bogota.On Friday, Aug 27 I met Álvaro Torres for breakfast.He took me then to the Zerenia clinic.I had the opportunity to get through the 4 floor building and see the entire infrastructure.What I realized from the moment I entered the building was the high activity,it was packed with people and this was the same through the entire building.If I got it right,they had scheduled some 400 patients for that day.I met Ana the „clinic manager“.If I remember correct she is also in charge for HR.Later on I had an individual discussion with Jorge, „the leading doctor“ to get a feeling from him,his motivation etc.I met other senior members of the clinic and we had a great open discussions and I asked tons of questions (later that day,Alvaro said „Thomi, you asked many challenging questions“.We went for lunch where I met other team members and afterwards we went to the Khiron offices where I met Rodrigo (VP KhironMed),Juan Diego (Regulatory Affairs),Elsa (Marketing and Communication VP),Paola (IR) and others.Khiron has so many patient data’s collected with all the results… I would say (my opinion as usual),there is nobody around the globe with such a broad database. All the studies done so far from others have only a small number of participants. Khiron has probably data from more than a thousand patients, it’s effects etc. I wouldn’t be surprised if they use these real data’s (collected from doctors!) in discussions with Health Insurance companies or maybe even report in well known medical journals! Khiron will get everybody’s attention.

    I spent the entire day with them and I have to say that I was extremely impressed about the very positive energy and highly motivated team. You could literally feel the positive spirit and high level of engagement from every single person.

    My very personal view:
    Khiron has an excellent position, strong business model and basically no competition. The other companies in that sector and in the region are rather „farmers“, while Khiron has the entire chain from seed, the growing facility, production, the clinics, the doctors with all the thousands of patients (in other words, Khiron has the business where the big margin is). Khiron has all in their hands from seed up to the sale to the final patient. This is in my view unique in the industry. With the growth they have shown and expected growth to come, their recently announced guidance, I personally expect Khiron to be cash-flow neutral by end of Q4 2022 and in 1st half of 2023 they should become free cash flow positive and profitable. This could probably be achieved earlier but I don’t want that… as I want to see continued investments in Brazil, Mexico etc…. Investments today should result in further growth, cash-flow generation and profitability later one. The unique business model without any competition out there could actually make them a take over target. I don’t expect this to happen tomorrow, competition (the pharmaceutical industry) is probably on the side line and observing if the business model works. If Khiron executes successfully their plans, they will dominate LatAm, eventually also Germany/UK but my focus is now on LatAm (a region I traveled a few dozen times as I covered the region seeing my clients and I was LatAm based too). If they get the “pharma business”, the pharma industry will not just look and see their market shrink, they can make it up buy buying Khiron at a nice premium. This seems to me a reasonable possibility maybe by 2024.

    This represents my own personal view and expectation. I traveled at own costs from Switzerland to Colombia, am of course not compensated. I am simply an interested shareholderonly share my personal opinion, personal view. I am not giving any advice nor recommendation, only share my personal view. Everybody has to make an own decision with all its consequences and don’t blame others for your decision. One thing is clear to me… we all know Microsoft, Apple, Amazon, Shopify…. They were losing in some cases money for over 20 years, always reinvested to get future growth. The same is the case with Khiron. It takes time, it won’t happen over night. Yes, the share price has been frustrating, but if they execute, cash flow and profitability comes, then it is a question of time until the share price follows - that’s a natural development. People looking for a quick win should buy a lottery ticket at the next corner and not invest in shares as this is a long term investment. Longterm doesn’t meant 6, 12, 18 months. We are talking years. If people don’t understand that, don’t but shares - especially not in a new emerging industry. I will keep my shares for sure at least until end of 2024 but probably rather longer, unless a take over offer is on the
  • J
    Jonn
    Buying another $200k of shares? Good use of the money lol
  • j
    james
    they are buying 8 million shares at market---2 million dollars worth. the train is moving up today.
  • J
    Jonn
    Whopping 32k shares traded so far today! Why isn't the buyback happening? I'm sure there's some excuse management will use at it's next earnings call.
  • j
    james
    by the way. just bought 50000 more shares to reduce my cost average.
  • J
    Jonn
    Look at that volume 10K shares so far. So close to completing that 5million commitment. Should have this wrapped by 2030.
  • M
    MoonShot
    As we continue to expand our clinic and patient networks, partnerships with insurance providers, and distribution channels, we anticipate that global medical cannabis revenues will reach $1 million per month by Q1 2022. In addition, we anticipate that revenues from Health Services will stabilize at $1 million per month, consistent with levels achieved in March 2021," continued Alvaro Torres.
  • D
    DFV_Fan
    There are no legal Medical Cannabis companies selling Cannabis in Mexico at the moment. This is a regulations / red tape problem specific to Mexican bureaucracy not a Khiron problem. Perhaps we need to wait for rec for things to get sorted?
  • k
    kalle
    but some more,good entry point, easily dbl your money...
  • a
    aasdfd
    Baggies hopeful for buy back. It ain't happening it's just a poor attempt to prop the price. Company ain't even a going concern🤦‍♂️. Remember last time they announced a buyback claiming they had a strong cash position just to do 50% dilution to keep the lights on. Lmao!